Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2003 | 2 |
2004 | 1 |
2005 | 2 |
2006 | 1 |
2007 | 1 |
2011 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Efficacy of tegaserod in chronic constipation in men.
Am J Gastroenterol. 2007 Feb;102(2):362-70. doi: 10.1111/j.1572-0241.2006.00988.x. Epub 2006 Dec 11.
Am J Gastroenterol. 2007.
PMID: 17156137
Clinical Trial.
Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
Müller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Löffler H.
Müller-Lissner S, et al. Among authors: rueegg p.
Aliment Pharmacol Ther. 2005 Jan 1;21(1):11-20. doi: 10.1111/j.1365-2036.2004.02294.x.
Aliment Pharmacol Ther. 2005.
PMID: 15644040
Free article.
Clinical Trial.
Item in Clipboard
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Worth H, Chung KF, Felser JM, Hu H, Rueegg P.
Worth H, et al. Among authors: rueegg p.
Respir Med. 2011 Apr;105(4):571-9. doi: 10.1016/j.rmed.2010.11.027. Epub 2011 Jan 11.
Respir Med. 2011.
PMID: 21227674
Free article.
Item in Clipboard
Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects.
Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D.
Coffin B, et al. Among authors: rueegg p.
Aliment Pharmacol Ther. 2003 Feb 15;17(4):577-85. doi: 10.1046/j.1365-2036.2003.01449.x.
Aliment Pharmacol Ther. 2003.
PMID: 12622767
Free article.
Clinical Trial.
Item in Clipboard
Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials.
Müller-Lissner S, Koch G, Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf C, Lefkowitz M.
Müller-Lissner S, et al. Among authors: rueegg p.
J Clin Epidemiol. 2003 Apr;56(4):310-6. doi: 10.1016/s0895-4356(03)00027-1.
J Clin Epidemiol. 2003.
PMID: 12767407
Item in Clipboard
A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
Tack J, et al. Among authors: rueegg p.
Gut. 2005 Dec;54(12):1707-13. doi: 10.1136/gut.2005.070789. Epub 2005 Jul 14.
Gut. 2005.
PMID: 16020489
Free PMC article.
Clinical Trial.
Item in Clipboard
Tegaserod does not alter fasting or meal-induced biliary tract motility.
Fisher RS, Thistle J, Lembo A, Novick J, O'Kane P, Chey WD, Beglinger C, Rueegg P, Shi V, Dogra A, Luo D, Earnest DL.
Fisher RS, et al. Among authors: rueegg p.
Am J Gastroenterol. 2004 Jul;99(7):1342-9. doi: 10.1111/j.1572-0241.2004.30301.x.
Am J Gastroenterol. 2004.
PMID: 15233676
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite